Shares of Canopy Growth Corporation (NASDAQ:CGC – Get Free Report) have received an average rating of “Hold” from the seven research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company.
CGC has been the topic of several research analyst reports. Weiss Ratings cut shares of Canopy Growth from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 18th. Wall Street Zen cut shares of Canopy Growth from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. ATB Cormark Capital Markets upgraded shares of Canopy Growth from a “strong sell” rating to a “moderate buy” rating in a report on Tuesday, March 17th. Canaccord Genuity Group started coverage on shares of Canopy Growth in a report on Friday, March 27th. They issued a “buy” rating on the stock. Finally, Alliance Global Partners restated a “neutral” rating on shares of Canopy Growth in a report on Saturday, February 7th.
Get Our Latest Stock Analysis on Canopy Growth
Institutional Inflows and Outflows
Canopy Growth Price Performance
CGC opened at $1.12 on Friday. The company’s 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.14. The company has a debt-to-equity ratio of 0.30, a quick ratio of 4.26 and a current ratio of 5.34. Canopy Growth has a 1 year low of $0.84 and a 1 year high of $2.38. The stock has a market capitalization of $452.61 million, a PE ratio of -0.86 and a beta of 0.78.
About Canopy Growth
Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.
The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.
Featured Stories
- Five stocks we like better than Canopy Growth
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
